VascVersa to Showcase Breakthrough Regenerative Medicine Platforms at BIO-Partnering London
VascVersa is pleased to announce its participation in BIO-partnering at London Life Sciences Week (16-19th November 2026), where the Company will showcase its pioneering Angicyte® and AngiGenix™ platforms, novel regenerative medicine technologies focused on stimulating vascular repair, promoting functional blood vessel formation, and addressing the underlying causes of ischaemic disease. These innovative platforms have the potential to transform the treatment of ischaemic retinal diseases by targeting the underlying vascular dysfunction that drives vision loss.
Chief Technical Officer Timothy Allsopp will host a series of strategic partnering and investor meetings with global pharmaceutical companies and biotechnology and healthcare investors to explore investment opportunities, collaboration, licensing and co-development. VascVersa is seeking partners who share its vision of developing next-generation treatments capable of restoring visual function, preserving vision and delivering meaningful improvements in patient outcomes. These discussions will support the company’s ongoing fundraising activities and strategy to accelerate platform development, expand commercial partnerships, and advance towards key clinical milestones.



